BDNF and Nootropics

Brain-Derived Neurotrophic Factor (BDNF) plays a well-characterized role in synaptic plasticity, neuronal survival, neurogenesis, and resilience to depression and other neuropsychiatric disorders.

Most importantly, BDNF provides trophic support for existing neurons while encouraging the reorganization, growth and regeneration of new neurons and synapses.

BDNF is an endogenous neuropeptide that activates the TrkB receptor, and is biologically active in the hippocampus, cortex, and basal forebrain-areas essential to higher-order cognition. BDNF may also modulate the activity of neurotransmitters, including the alpha-7 nicotinic acetylcholine receptor.

The val66met is a relatively common polymorphism affecting the BDNF protein that is linked to the development of mood disorders.

Because of the importance of BDNF in regulating neuroplasticity into adulthood, BDNF has been suggested to play an essential role in the development of neurodegenerative disease. Numerous lines of evidence indicate that BDNF gene expression and its high-affinity receptor (Trk B) are reduced in post-mortem brain region from patients suffering from neurodegenerative disease.

The Challenges of Delivery To The CNS

As decreased circulating BDNF has been observed in Alzheimer’s disease (AD), one might imagine that exogenously delivering BDNF into the brain might be a valuable therapeutic strategy. However, BDNF does not readily cross the blood brain barrier (BBB), may result in Trk B receptor down regulation, and increases neuronal excitability. Therefore, crudely pumping BDNF into the CNS could hypothetically result in seizures.

When administered intraventricularly or intrathecally, BDNF infusion results in little BBB penetration, which may explain why clinical trials using this approach have been disappointing.

Biomedical scientists have turned to other more indirect strategies to enhance BDNF signaling. However, clinical trials are also viral vector based strategies to insert a promoter upstream of the BDNF gene that would dramatically enhance gene expression. One such pharmaceutical company pursuing this approach is Sangamo Biosciences.

Classes of drugs, nutraceuticals and lifestyle factors that Increase BDNF or Indirectly Enhance BDNF signaling include the following:

Antidepressants
AMPA Receptor Modulators
Estrogens
Cannabinoids
GABA-B Antagonists
Phosphodiesterase Inhibitors
Lithium
Peptide BDNF Mimetics
Nutraceuticals (Gingko biloba, zinc, D-serine and others)
Exercise and Dietary Flavonoids and Anthocyanins (especially blueberries and cacao flavonoids)
Calorie Restriction
Cognitive Stimulation
Sleep Deprivation

References

Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011;10(3):209-19.
Fumagalli F, Racagni G, Riva MA. The expanding role of BDNF: a therapeutic target for Alzheimer’s disease?. Pharmacogenomics J. 2006;6(1):8-15.

One thought on “BDNF and Nootropics

  1. Yuri Zhivago says:

    After using Dihexa is any other known BDNF agent even worth taking?
    Example:
    Noopept has effect 500x BDNF.
    Dihexa has 10,000,000 times effect.

    What about synergism? Additive effects? Wasted time and money?

    Yuri

Comments are closed.

-6566 Days 5 Hours 16 Minutes 30 Seconds LIMITED OFFER BUY $200 GET 10%
BUY Now